25gmds159 10.3205/25gmds159 urn:nbn:de:0183-25gmds1597 Meeting Abstract Dignass Dignass Axel A

Agaplesion Markus Hospital, Department of Medicine I, Frankfurt am Main, Germany

author Blumenstein Blumenstein Irina I

Goethe University Frankfurt, University Hospital, Medical Clinic 1, Frankfurt am Main, Germany

author Schwedhelm Schwedhelm Carolina C

Pfizer Pharma GmbH, Berlin, Germany

author Strassen Strassen Katrin K

Gesundheitsforen Leipzig GmbH, Leipzig, Germany

author Kunk Kunk Leonie L

Pfizer Pharma GmbH, Berlin, Germany

author Marquardt Marquardt Sophie S

Gesundheitsforen Leipzig GmbH, Leipzig, Germany

author Seiffert Seiffert Anna A

Gesundheitsforen Leipzig GmbH, Leipzig, Germany

author Kulchytska Kulchytska Nataliia N

Pfizer Pharma GmbH, Berlin, Germany

author Benson Benson Alexa A

Gesundheitsforen Leipzig GmbH, Leipzig, Germany

author Kisser Kisser Agnes A

Pfizer Pharma GmbH, Berlin, Germany

author German Medical Science GMS Publishing House

Düsseldorf

610 ulcerative colitis HCRU medical costs real-world data advanced therapy inadequate response 20251103 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0631 159 Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie 70. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS) PS 9: Epidemiologie 2 Jena 20250907 20250911 Abstr. 54 Pfizer TextIntroduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes significant morbidity and impaired quality of life . In Germany, approximately 5.3 per 1,000 adults are affected . Recent studies showed that most adult patients initiating advanced therapy (72-82%) exhibit an inadequate response (IR) , . This study builds on the previous research to evaluate healthcare resource utilization (HCRU) and medical costs among adult UC patients with and without IR to their first advanced therapy.Methods: This non-interventional, retrospective study used claims data from the German Analysis Database for Evaluation and Health Services Research (DADB) – managed by Gesundheitsforen Leipzig GmbH – assessed adult UC patients initiating their first advanced treatment between 2016 and 2021. The DADB includes data from 15 statutory health insurers and is representative in terms of age and sex of the broader German population. IR to therapy was defined as exhibiting ≥ 1 of 8 predefined criteria (i.e., dose escalation, therapy switch, augmentation with conventional therapy, prolonged use of corticosteroids, therapy discontinuation, UC-related surgery, UC-related hospitalization, anti-diarrheal prescriptions) during the 12 months following prescription . HCRU and direct medical costs were calculated for outpatient and inpatient care and medication.Results: In 2021, 334 UC patients initiated advanced treatment, among which 239 (72%) exhibited IR [2]. Overall visits to general practitioners (GP), gastroenterologists, and other specialists were on average 5.3, 3.8, and 11.9 times per patient, respectively. Most of all GP visits (72.2%) and gastroenterologist visits (81.6%) were UC-related, compared to only 19.3% of other specialist visits. Number of and costs for outpatient visits were similar among patients with and without IR. The main cost burden was attributable to medication. Patients with IR had on average a higher number of all-cause and UC-related prescriptions than patients without IR (35 vs 22 all cause; 15 vs 10 UC-related). Accordingly, medication costs were higher in patients with IR (25,002€ vs 21,713€ all-cause; 19,516€ vs 18,643€ UC-related). 86 (26%) patients had ≥ 1 hospitalization, of which 29 (34%) had ≥ 1 UC-related hospitalization. Patients with IR had on average more (1.6 vs 1.0) and longer (10.1 vs 2.7 days) all-cause hospitalizations than patients without IR. Due to the IR definition, all patients with UC-related hospitalizations were in the IR cohort, with an average of 1.7 hospitalizations, each lasting on average 16.4 days. Mean costs for inpatient care were higher for hospitalized IR patients compared to hospitalized patients without IR (€10,242 vs €2,220 all-cause; €12,562 UC-related). While mean number of hospitalizations remained stable across the study years (2016-2021), the mean duration and costs for inpatient care increased.Conclusion: Patients with IR to UC advanced therapy had 59% more medication prescriptions, 60% higher hospitalization rates and hospital stays that were nearly triple in length (274%), leading to increased outpatient and inpatient costs. Ensuring adequate treatment response is crucial to minimizing unnecessary hospitalizations and medical costs. Further research focusing on identifying predictive factors for IR and evaluating alternative treatment strategies is needed to improve patient outcomes and reduce burden on healthcare systems.This study was funded by Pfizer. Carolina Schwedhelm, Leonie Kunk, Nataliia Kulchytska, and Agnes Kisser are employed by Pfizer Pharma GmbH in Germany. Sophie Marquardt, Katrin Strassen, Anna Seiffert, and Alexa Benson are employees of Gesundheitsforen Leipzig GmbH, which is a paid consultant of Pfizer Pharma GmbH for designing the study, carrying out the analyses, and interpreting the results. Irina Blumenstein reports consulting and lecturer fees from AbbVie, Amgen, Biogen, Janssen-Cilag, Celgene/BMS GmbH, Celltrion, Falk Foundation, Fresenius Kabi, Galapagos, Lilly, Merck, Pharmacosmos, Pfizer, Takeda, Tillotts. Axel Dignass reports received fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees from Abivax, AbbVie, Bristol Myers Squibb, Dr Falk Foundation, Galapagos, Gilead, J&J, and Pfizer; consultancy fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, J&J, Lilly, MSD, Pfizer, Pharmacosmos, Roche, Sandoz, Stada, Takeda, Tillotts, and Vifor Pharma; payment for lectures including service on speakers bureaus from AbbVie, Biogen, CED Service GmbH, Celltrion, Falk Foundation, Ferring, Galapagos, Gilead, High5MD, J&J, Materia Prima, MedToday, MSD, Pfizer, Sandoz, Takeda, Tillotts, and Vifor Pharma; payment for manuscript preparation from Abbvie, Falk Foundation, J&J, Takeda, Thieme, and UniMed Verlag.The authors declare that an ethics committee vote is not required. Armuzzi A Liguori G Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review 2021 Dig Liver Dis 803-8 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis. 2021;53(7):803-8. Dignass A Blumenstein I Schwedhelm C Strassen K Kunk L Marquardt S Seiffert A Kulchytska N Hänsel I Benson A Kisser A Inadequate Therapy Response on Advanced Therapy in Ulcerative Colitis Adult Patients: A Retrospective Analysis of German Health Claims Data 2025 United European Gastroenterol J 710-8 Dignass A, Blumenstein I, Schwedhelm C, Strassen K, Kunk L, Marquardt S, Seiffert A, Kulchytska N, Hänsel I, Benson A, Kisser A. Inadequate Therapy Response on Advanced Therapy in Ulcerative Colitis Adult Patients: A Retrospective Analysis of German Health Claims Data. United European Gastroenterol J. 2025;13(5):710-8. Bokemeyer B Picker N Wilke T Rosin L Patel H Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data 2022 Inflamm Bowel Dis 1647-57 Bokemeyer B, Picker N, Wilke T, Rosin L, Patel H. Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data. Inflamm Bowel Dis. 2022;28(11):1647-57. 0 0 0 0